Acadia Healthcare (NASDAQ:ACHC) Given New $91.00 Price Target at Barclays

Acadia Healthcare (NASDAQ:ACHC) had its target price cut by stock analysts at Barclays from $100.00 to $91.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 33.37% from the stock’s previous close.

ACHC has been the subject of a number of other research reports. TD Cowen lifted their target price on shares of Acadia Healthcare from $86.00 to $101.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Mizuho lifted their target price on shares of Acadia Healthcare from $77.00 to $84.00 and gave the company a “neutral” rating in a research report on Wednesday, March 6th. Deutsche Bank Aktiengesellschaft upgraded Acadia Healthcare from a “sell” rating to a “hold” rating and set a $70.00 target price for the company in a research report on Thursday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $94.00 price target on shares of Acadia Healthcare in a research report on Monday, March 4th. Finally, UBS Group lifted their price objective on Acadia Healthcare from $88.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $91.00.

Acadia Healthcare Stock Performance

Shares of Acadia Healthcare stock traded down $4.76 during trading hours on Thursday, reaching $68.23. The company’s stock had a trading volume of 630,731 shares, compared to its average volume of 571,479. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.67 and a current ratio of 0.67. Acadia Healthcare has a one year low of $66.49 and a one year high of $87.77. The company’s 50 day simple moving average is $77.49 and its 200 day simple moving average is $77.68. The stock has a market cap of $6.31 billion, a P/E ratio of -273.23, a price-to-earnings-growth ratio of 2.18 and a beta of 1.31.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.84 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.04. The company had revenue of $768.10 million during the quarter, compared to analyst estimates of $779.20 million. Acadia Healthcare had a negative net margin of 0.74% and a positive return on equity of 11.21%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 earnings per share. As a group, analysts expect that Acadia Healthcare will post 3.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Wade D. Miquelon sold 2,203 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.39, for a total value of $188,114.17. Following the completion of the transaction, the director now owns 46,074 shares in the company, valued at approximately $3,934,258.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Acadia Healthcare

Several large investors have recently modified their holdings of the business. Handelsbanken Fonder AB increased its position in shares of Acadia Healthcare by 16.3% during the third quarter. Handelsbanken Fonder AB now owns 14,274 shares of the company’s stock worth $1,004,000 after acquiring an additional 2,000 shares in the last quarter. Raymond James & Associates boosted its position in Acadia Healthcare by 0.6% during the 3rd quarter. Raymond James & Associates now owns 76,048 shares of the company’s stock worth $5,347,000 after acquiring an additional 424 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Acadia Healthcare by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 1,258,459 shares of the company’s stock valued at $88,482,000 after purchasing an additional 13,765 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Acadia Healthcare by 20.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,920 shares of the company’s stock worth $1,330,000 after purchasing an additional 3,167 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in Acadia Healthcare by 1.3% during the third quarter. Mackenzie Financial Corp now owns 15,737 shares of the company’s stock worth $1,063,000 after purchasing an additional 199 shares during the last quarter.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.